Search clinical trials for: NNC 0070-0002-0182

Total 186 results

Janssen Research & Development, LLC

Completed

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Inflammation | Crohn's Disease

Belgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
Novo Nordisk A/S

Terminated

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (paradigm™ 2)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Germany, Japan
Novo Nordisk A/S

Withdrawn

Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers

Obesity | Metabolism and Nutrition Disorder
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Completed

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

United Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
Novo Nordisk A/S

Completed

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Inflammation | Healthy | Rheumatoid Arthritis | Systemic Lupus Erythematosus

Netherlands
Novo Nordisk A/S

Withdrawn

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Terminated

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (pathfinder™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Germany, Switzerland, United Kingdom, Italy, Japan, Turkey
Shanghai HyaMab Biotech Co.,Ltd.

Completed

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Locally Advanced/Metastatic Solid Tumors

United States
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A Study of HY-0102 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
VA Office of Research and Development

Withdrawn

TTI-0102 for Veterans With TBI

Posttraumatic Stress Disorder | Mild to Moderate TBI

United States
M.D. Anderson Cancer Center

Withdrawn

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Carcinoid Syndrome | Advanced Neuroendocrine Neoplasm
Assaf-Harofeh Medical Center

Unknown

Go For It: to Improve Levels of Daily Physical Activity and to Reduce the Sedentary Life Style of Adolescents With CP

Cerebral Palsy (CP)
TRYP Therapeutics

Recruiting

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome

United States
Oui Therapeutics, Inc.
National Institute of Mental Health (NIMH)

Enrolling by invitation

A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

Suicidal Ideation | Suicide, Attempted

United States
Dr. Noah Biotech Inc.

Completed

Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers

Stroke | Stroke Sequelae

Korea, Republic of
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
TRYP Therapeutics

Active, not recruiting

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Binge Eating Disorder

United States
GWT-TUD GmbH
Miltenyi Biomedicine GmbH

Terminated

Immunoadsorption in Patients With Severe Systemic Sclerosis

Systemic Scleroderma

Germany
Ottawa Hospital Research Institute

Completed

Digital Versus Analog Pleural Drainage Following Pulmonary Resection (DiVA Phase II)

Lobectomy | Segmentectomy | Pulmonary Air Leak | Wedge Resection

Canada
NHS Tayside
University of Dundee

Completed

Orthodontic Reduction of an Increased Overbite in Adolescents - the Mechanism and Rate of Occlusal Adaptation

Increased Overbite

United Kingdom
Alfredo Gamboa
Vanderbilt University Medical Center

Active, not recruiting

Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)

Postural Tachycardia Syndrome | Postural Orthostatic Tachycardia Syndrome

United States
Mridula George, MD
National Cancer Institute (NCI); Incyte Corporation; Oncolytics Biotech

Recruiting

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Triple-negative Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Alvogen Korea

Completed

Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers

Healthy

Korea, Republic of
HaEmek Medical Center, Israel
Carmel Medical Center

Unknown

Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope (VISUAL)

Respiratory Distress Syndrome

Israel
National Institute for Tuberculosis and Lung Diseases...

Recruiting

PEP and OPEP Devices in Cystic Fibrosis

Cystic Fibrosis

Poland
Wake Forest University Health Sciences

Active, not recruiting

SNIFF Multi-Device Study 2

Cognitive Impairment | Mild Cognitive Impairment

United States
Assistance Publique - Hôpitaux de Paris
Laboratoire Crinex

Completed

VITamine D Supplementation in RenAL Transplant Recipients - VITALE (VITALE)

Renal Transplant Candidate for Right Kidney

France
Alvogen Korea

Completed

Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers

Healthy

Korea, Republic of
Magna Pharmaceuticals, Inc.

Withdrawn

Study of AHIST in Seasonal Allergic Rhinitis Patients

Rhinitis, Allergic, Seasonal

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Uniwersytecki Szpital Kliniczny w Opolu

Recruiting

Vitamin D3 Supplementation in Critically Ill Patients Undergoing CRRT (NephroD)

Vitamin D3 Deficiency

Poland
Adele Sparavigna

Unknown

Tolerance and Efficacy Evaluation of 3 Face Creams (FILLER)

Skin Aging

Italy

Search clinical trials for: NNC 0070-0002-0182

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations